H.C. Wainwright lowered the firm’s price target on Sana Biotechnology (SANA) to $8 from $11 and keeps a Buy rating on the shares. The firm adapted its model to remove SC291 oncology sales, and have instead modeled SC262 in the post-CD19 CAR-T setting, which is a smaller market opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology downgraded to Market Perform from Outperform at JMP Securities
- Sana Biotechnology to focus on SC291, suspends SC291 in oncology and SC379
- SANA Upcoming Earnings Report: What to Expect?
- Sana Biotechnology Announces Leadership and CFO Transition
- Sana Biotechnology CFO Nathan Hardy resigns, effective October 4